Among listed 2017 presenters/companies “who should attend" are two outliers; both with close ties to Northwest, a history of coordinating deals with each other, and a shared primary relevance to Northwest that indicates their inclusion as suggested attendees was specified by the event sponsor when planning the event. They are: 1. Woodford Investment Management and 2. The Life Sciences Division (https://beta.companieshouse.gov.uk/company/05909336/filing-history), founded in June 2016 by Northwest’s non-executive director Dr. Navid Malik, who was head of the life sciences research division at Cenkos Securities from 2012 through late 2015 spanning Woodford's widely publicized investments in Northwest. It is likely that Woodford consulted Dr. Malik regarding NWBO investments, in light of both Dr. Malik’s role as a Northwest director and Woodford’s well-established relationship with Cenkos dating back as early as 2008:
2. http://www.cityam.com/212610/british-banking-model-makes-comeback “Cenkos wants to lead the charge. Just a couple of years ago it was dismissed by the big boys as an outfit with an unimpressive future. But the boutique made waves last year with the successful £1.4bn flotation of the AA. [...] The model is one of pushing personal contacts hard, matching big investors with innovative deals. [...] “It appeals to people with confidence in their own ability to do the deal without the support of a large organisation,” said analyst Mark Thomas from Edison Investment Research [...]A senior executive at a rival was more blunt: “Cenkos are pushy,” he said. “They have a strong relationship with the ex-Invesco man [Neil Woodford], which has generated a lot of business for them. But they’re highly profitable and very successful.” [...]“They punch well above their weight. They’ve got institutional reach and the institutions that invest in their projects are all blue chip.”“
Ignoring Dr. Malik’s eventual split from Cenkos precipitated by the anonymous Phase V short report, Dr. Malik has a PhD in Drug Delivery on top of masters/bachelors degrees in other bio fields. Woodford had reason to consult Malik in 2014/2015, and it’s possible that Woodford and his funds are still in the cards.
“Dr. Malik has been one of the most influential analysts in the UK and Europe over the last decade, covering the life sciences industry worldwide. In 2011, Dr. Malik was awarded two Starmine Awards (awarded each year by Thomson Reuters and the Financial Times): Number One Stock Picker in the European Pharmaceutical Sector, and Number Two Stock Picker in the UK and Ireland Healthcare Sector. Dr. Malik has built life science teams and franchises at multiple large financial institutions in London, which completed IPOs and secondary stock offerings for small biotech and life sciences companies totaling over $700 million in recent years, and which also initiated research coverage on dozens of small life sciences companies in addition to covering large pharmaceutical, biologics and healthcare companies. Dr. Malik holds a PhD in Drug Delivery within Pharmaceutical Sciences, as well as degrees in Biomedical Sciences Research (M.Sc.) and Biochemistry and Physiology (B.Sc., joint honors). Dr. Malik also holds an MBA in finance."
Market Data 
Markets 
AI
